Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genzyme | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genzyme

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme

4Q Revenue: $854.2 million (+17%)

4Q Earnings: $209 million (+29%)

FY Revenue: $3.2 billion (+17%)

FY Loss: $16.8 million (earnings were $441.5 million FY2005)

Comments: Myozyme for Pompe disease was launched in Europe and the U.S. in 2Q2006, and sales for the year were $59 million. Fabrazyme sales were $359 million and Cerezyme sales were $1 billion for the year. Sales of Renagel were $515 million and sales of Synvisc were $234 million for the year. FY Loss includes a charge of $552.9 million related to in-process R&D acquired from AnorMED. R&D expenses in the quarter were $166.4 million, up 20% and were $650 million for the year, up 29%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters